We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.

CASE5221 Study

Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors

pancreatic cancer

 

AGE: 18+ years old
GENDER: All
HEALTHY PARTICIPANTS: No
CONDITION: Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor (pNET)
TYPE: Interventional Study
LOCATION: UH Cleveland Medical Center

Learn More About This Research Study

To learn more about this study, please call study coordinator, Debbie Donohue at 216-844-4784 or complete the online form below.

Study Purpose

The purpose of this study is to evaluate recurrence-free survival in participants with resected pancreatic neuroendocrine tumors (pNETs) randomized to treatment with capecitabine + temozolomide (CAPTEM) compared to observation only.

Who Can Participate

Participants 18 years old and older diagnosed with diagnosed with pancreatic neuroendocrine carcinoma or have metastatic malignant neoplasm in the liver may be eligible for this study.

To learn more about this study, please fill out the form below to request more information.
XXX-XXX-XXXX
I'm not a robot